Canadian Cord-Blood Procedure Passes Key Milestone in Cancer Trial

June 28, 2018

(The Globe and Mail) – Researchers behind a made-in-Canada technology for multiplying the number of stem cells that can be derived from donated cord blood say they are ready to move on to the next phase in their effort to prove the technology can save lives. Last week, the 25th and final patient to be admitted into a clinical trial of the technology was given a transfusion of stem cells derived from cord blood. The stem cells are used to regenerate the body’s capacity to make healthy blood cells in patients with severe forms of blood cancer including acute leukemia.

Recommended Reading